Stone investor group reports 16.61% stake in Scinai Immunotherapeutics (SCNI)

Rhea-AI Filing Summary

Scinai Immunotherapeutics Ltd. disclosed that investor Daniel E. Stone and RK Stone Miami, LLC together beneficially own 584,534 American Depositary Shares (ADSs), representing 16.61% of the ADS class. Each ADS represents 4,000 ordinary shares. Stone individually reports 346,667 ADSs with sole voting and dispositive power, while RK Stone Miami, LLC reports 237,867 ADSs with sole voting and dispositive power.

The filing explains that RK Stone Miami, LLC holds ADSs and pre-funded warrants that cannot be exercised if this would raise its beneficial ownership, together with affiliates and certain other persons, above 9.99% of the issuer’s ordinary shares. The reporting persons certify the securities are not held for the purpose of changing or influencing control of the company.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

Scinai Immunotherapeutics Ltd.

(Name of Issuer)

American Depositary Shares, each representing 4,000 Ordinary Shares, no par value

(Title of Class of Securities)

09073Q203

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 09073Q203

1

Names of Reporting Persons

STONE DANIEL E.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 346,667.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 346,667.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

346,667.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 09073Q203

1

Names of Reporting Persons

RK Stone Miami, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FLORIDA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 237,867.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 237,867.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

237,867.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.71 %

12

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: Based on 13,872,899,584 ordinary shares outstanding as of December 31, 2025, as disclosed by the issuer on February 15, 2026. Includes 107,000 American Depositary Shares (ADSs) held directly by the Reporting Person, 200,000 ADSs held by RK Stone Miami, LLC ("RK") and 37,867 ADSs issuable upon exercise of pre-funded warrants held by RK. On September 22, 2025, RK exercised 200,000 warrants. As of December 31, 2025, RK holds 200,000 ADSs and 283,426 ADS pre-funded warrants, which may not be exercised if such exercise would result in beneficial ownership by RK, together with its affiliates (which include the Reporting Person) and certain other persons, of greater than 9.99% of the ordinary shares. As disclosed in the Schedule 13G amendment filed with the Securities and Exchange Commission on January 24, 2025, future issuances of ordinary shares or ADSs by the issuer to third parties are expected to cause additional amounts of pre-funded warrants to become exercisable within the foregoing limitation, without increasing the reporting person's beneficial ownership percentage.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Scinai Immunotherapeutics Ltd.
(b)	Address of issuer's principal executive offices: JERUSALEM BIOPARK, 2ND FLOOR, HADASSAH EIN KEREM CAMPUS, JERUSALEM, ISRAEL 00000
Item 2.
(a)	Name of person filing: STONE DANIEL E. RK Stone Miami, LLC
(b)	Address or principal business office or, if none, residence: 1200 BRICKELL AVENUE, #1470 MIAMI, Florida 33131
(c)	Citizenship: STONE DANIEL E. - UNITED STATES RK Stone Miami, LLC - FLORIDA
(d)	Title of class of securities: American Depositary Shares, each representing 4,000 Ordinary Shares, no par value
(e)	CUSIP No.: 09073Q203
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 584,534
(b)	Percent of class: 16.61 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: STONE DANIEL E. - 346,667 RK Stone Miami, LLC - 237,867
	(ii) Shared power to vote or to direct the vote: STONE DANIEL E. - 0 RK Stone Miami, LLC - 0
	(iii) Sole power to dispose or to direct the disposition of: STONE DANIEL E. - 346,667 RK Stone Miami, LLC - 237,867
	(iv) Shared power to dispose or to direct the disposition of: STONE DANIEL E. - 0 RK Stone Miami, LLC - 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

STONE DANIEL E.

Signature:	/s/ Daniel E. Stone
Name/Title:	Stone Daniel E.
Date:	02/13/2026

RK Stone Miami, LLC

Signature:	/s/ Daniel E. Stone
Name/Title:	Sole Member - RK Stone Miami, LLC
Date:	02/13/2026

FAQ

What ownership stake in Scinai Immunotherapeutics (SCNI) does Daniel E. Stone report?

Daniel E. Stone reports beneficial ownership of 584,534 ADSs of Scinai Immunotherapeutics, equal to 16.61% of the ADS class. This includes ADSs held directly, through RK Stone Miami, LLC, and ADSs issuable upon exercise of pre-funded warrants.

How many Scinai Immunotherapeutics ADSs does RK Stone Miami, LLC hold?

RK Stone Miami, LLC reports beneficial ownership of 237,867 ADSs of Scinai Immunotherapeutics. It has sole voting and dispositive power over these ADSs, and also holds pre-funded warrants subject to a 9.99% beneficial ownership limitation.

What percentage of Scinai Immunotherapeutics (SCNI) does 584,534 ADSs represent?

The filing states that beneficial ownership of 584,534 ADSs represents 16.61% of the class. This percentage is based on 13,872,899,584 ordinary shares outstanding as of December 31, 2025, as disclosed by the issuer.

Are RK Stone Miami’s pre-funded warrants in SCNI subject to an ownership cap?

Yes. The pre-funded warrants held by RK Stone Miami, LLC cannot be exercised if exercise would cause beneficial ownership by RK, its affiliates, and certain others to exceed 9.99% of the ordinary shares, limiting further ownership increases through warrant exercise.

Did RK Stone Miami, LLC exercise any Scinai Immunotherapeutics warrants in 2025?

The filing notes that on September 22, 2025, RK Stone Miami, LLC exercised 200,000 warrants. As of December 31, 2025, it then held 200,000 ADSs and 283,426 ADS pre-funded warrants, subject to the 9.99% beneficial ownership limitation.

Are the SCNI securities held by Daniel E. Stone intended to influence control of the company?

The reporting persons certify the securities were not acquired and are not held for the purpose of changing or influencing control of Scinai Immunotherapeutics, and are not part of any transaction with that purpose or effect, aside from limited nomination activities.